Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Alpha- Antitrypsin Deficiency Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 12 Oct 16

Research and Markets has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016" report to their offering.

'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016'; Alpha- Antitrypsin Deficiency pipeline therapeutics constitutes close to 21 molecules. Out of which approximately 21 molecules are developed by Companies.

Furthermore, the publisher says; Alpha- Antitrypsin Deficiency Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

The report 'Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies.

It also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 2, 1, 10 and 3 respectively.

Key Topics Covered:

  1. Introduction
  2. Alpha-Antitrypsin Deficiency Overview
  3. Therapeutics Development
  4. Pipeline Products for Alpha-Antitrypsin Deficiency - Overview
  5. Pipeline Products for Alpha-Antitrypsin Deficiency - Comparative Analysis
  6. Alpha-Antitrypsin Deficiency - Therapeutics under Development by Companies
  7. Alpha-Antitrypsin Deficiency - Therapeutics under Investigation by Universities/Institutes
  8. Alpha-Antitrypsin Deficiency Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Alpha-Antitrypsin Deficiency - Products under Development by Companies
  13. Alpha-Antitrypsin Deficiency - Products under Investigation by Universities/Institutes
  14. Alpha-Antitrypsin Deficiency - Companies Involved in Therapeutics Development
  • Adverum Biotechnologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Applied Genetic Technologies Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Carolus Therapeutics, Inc.
  • Cevec Pharmaceuticals GmbH
  • Dicerna Pharmaceuticals, Inc.
  • Digna Biotech, S.L.
  • Editas Medicine, Inc.
  • Grifols, S.A.
  • Inhibrx
  • Intellia Therapeutics, Inc.
  • International Stem Cell Corporation
  • Ionis Pharmaceuticals, Inc.
  • Kamada Ltd.
  • Polyphor Ltd.
  • ProMetic Life Sciences Inc.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 12/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.